Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

China flag China · Delayed Price · Currency is CNY
30.74
+0.24 (0.79%)
Mar 10, 2026, 10:15 AM CST
115.72%
Market Cap 12.37B
Revenue (ttm) 704.16M
Net Income (ttm) 22.23M
Shares Out 405.71M
EPS (ttm) 0.05
PE Ratio 556.60
Forward PE 210.34
Dividend n/a
Ex-Dividend Date n/a
Volume 2,903,920
Average Volume 5,798,375
Open 31.00
Previous Close 30.50
Day's Range 29.80 - 31.00
52-Week Range 12.45 - 34.68
Beta 0.51
RSI 61.03
Earnings Date Mar 20, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 463
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688319
Full Company Profile

Financial Performance

In 2025, SHA:688319's revenue was 704.16 million, an increase of 19.58% compared to the previous year's 588.86 million. Earnings were 22.23 million, an increase of 7.10%.

Financial Statements

News

There is no news available yet.